HK1104236A1 - Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin [d-meala]3-[etval]4 - Google Patents

Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin [d-meala]3-[etval]4

Info

Publication number
HK1104236A1
HK1104236A1 HK07112681.2A HK07112681A HK1104236A1 HK 1104236 A1 HK1104236 A1 HK 1104236A1 HK 07112681 A HK07112681 A HK 07112681A HK 1104236 A1 HK1104236 A1 HK 1104236A1
Authority
HK
Hong Kong
Prior art keywords
etval
meala
cyclosporin
treatment
infection
Prior art date
Application number
HK07112681.2A
Other languages
English (en)
Inventor
Pietro Scalfaro
Jean-Maurice Dumont
Gregoire Vuagniaux
Rolland-Yves R Mauvernay
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Publication of HK1104236A1 publication Critical patent/HK1104236A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK07112681.2A 2004-10-01 2007-11-21 Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin [d-meala]3-[etval]4 HK1104236A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2004003205 2004-10-01
PCT/IB2005/002940 WO2006038088A1 (en) 2004-10-01 2005-10-03 Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin

Publications (1)

Publication Number Publication Date
HK1104236A1 true HK1104236A1 (en) 2008-01-11

Family

ID=34959441

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07112681.2A HK1104236A1 (en) 2004-10-01 2007-11-21 Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin [d-meala]3-[etval]4

Country Status (30)

Country Link
US (3) US7439227B2 (ko)
EP (1) EP1793844B1 (ko)
JP (1) JP4892486B2 (ko)
KR (1) KR101191833B1 (ko)
CN (1) CN101056648B (ko)
AT (1) ATE490778T1 (ko)
AU (1) AU2005290984B2 (ko)
BR (1) BRPI0515494A (ko)
CA (1) CA2580448C (ko)
CY (1) CY1114594T1 (ko)
DE (1) DE602005025232D1 (ko)
DK (1) DK1793844T3 (ko)
EA (1) EA012650B1 (ko)
ES (1) ES2357587T3 (ko)
GE (1) GEP20104960B (ko)
HK (1) HK1104236A1 (ko)
HR (1) HRP20110169T1 (ko)
IL (1) IL182362A0 (ko)
MA (1) MA28950B1 (ko)
MX (1) MX2007003387A (ko)
NZ (1) NZ554412A (ko)
PL (1) PL1793844T3 (ko)
PT (1) PT1793844E (ko)
RS (1) RS51614B (ko)
SG (1) SG139750A1 (ko)
SI (1) SI1793844T1 (ko)
TN (1) TNSN07084A1 (ko)
UA (1) UA88484C2 (ko)
WO (1) WO2006038088A1 (ko)
ZA (1) ZA200702610B (ko)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
WO2006005610A1 (en) 2004-07-14 2006-01-19 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv)
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
ATE412005T1 (de) 2004-11-22 2008-11-15 Astellas Pharma Inc Zyklosporinanalog
AU2005322242B2 (en) 2004-12-23 2010-02-11 Novartis Ag Compositions for HCV treatment
CN101084005A (zh) * 2004-12-23 2007-12-05 诺瓦提斯公司 用于黄病毒科治疗的化合物
AR054778A1 (es) * 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
WO2007041631A1 (en) 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
CA2623865A1 (en) 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
CA2623898C (en) 2005-10-26 2013-12-24 Astellas Pharma Inc. New cyclic peptide compounds
NZ571826A (en) 2006-04-11 2012-01-12 Novartis Ag HCV/HIV inhibitors and their uses
DK2023918T3 (da) 2006-05-19 2011-04-26 Scynexis Inc Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
CN101557819A (zh) * 2006-10-12 2009-10-14 诺瓦提斯公司 修饰的环孢素的用途
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
JP5459545B2 (ja) 2007-05-02 2014-04-02 アステラス製薬株式会社 新規環状ペプチド化合物
AU2008304313B2 (en) 2007-09-26 2013-01-10 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) * 2008-02-08 2009-08-13 Debiopharm Sa Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
CA2724523A1 (en) 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
CA2741829A1 (en) * 2008-11-06 2010-05-14 Debio Recherche Pharmaceutique S.A. Cycloundecadepsipeptide compounds and use of said compounds as a medicament
CN102307892A (zh) 2008-12-31 2012-01-04 西尼克斯公司 环孢菌素a的衍生物
NZ594755A (en) 2009-01-30 2013-12-20 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
CA2782898A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011141891A1 (en) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Use of cycloundecadepsipeptide compounds
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
CN103153330B (zh) 2010-08-12 2017-08-18 美国科技环球有限公司 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用
WO2012045704A1 (en) * 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
CN103179966B (zh) 2010-10-08 2017-03-15 诺瓦提斯公司 磺酰胺ns3抑制剂的维生素e制剂
BR112013013166A2 (pt) * 2010-11-30 2016-09-06 Novartis Ag tratamentos da infecção pelo vírus da hepatite c
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
RU2013148539A (ru) 2011-03-31 2015-05-10 Новартис Аг Алиспоривир для лечения инфекции вируса гепатита с
EP2694087B1 (en) 2011-04-01 2015-01-28 Novartis AG Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
AR085988A1 (es) 2011-04-13 2013-11-13 Novartis Ag Tratamientos de la infeccion del virus de la hepatitis c
AU2012314517A1 (en) * 2011-09-27 2014-04-17 Novartis Ag Alisporivr for treatment of Hepatis C virus infection
SE1450019A1 (sv) 2011-10-21 2014-01-10 Abbvie Inc Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
MX2014004729A (es) 2011-10-21 2014-07-28 Abbvie Inc Tratamiento en combinacion (por ejemplo, con abt-072 o abt-333) de agentes antivirales de accion directa para utilizarse en el tratamiento del virus de la hepatitis c.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
KR20150013152A (ko) 2012-05-07 2015-02-04 노파르티스 아게 알리스포리비르를 이용한 약동학적 조절
AR090964A1 (es) 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
EP3038626A4 (en) 2013-08-26 2017-04-19 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
KR20200007863A (ko) 2017-05-12 2020-01-22 추가이 세이야쿠 가부시키가이샤 환상 유기 화합물의 제조 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
DE69928938T2 (de) * 1998-07-01 2006-08-17 Debiopharm S.A. Neues cyclosporin mit verbesserter wirkung
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20060252675A1 (en) 2006-11-09
USRE43371E1 (en) 2012-05-08
JP4892486B2 (ja) 2012-03-07
ES2357587T3 (es) 2011-04-27
US7439227B2 (en) 2008-10-21
WO2006038088A1 (en) 2006-04-13
SI1793844T1 (sl) 2011-05-31
NZ554412A (en) 2011-01-28
EA200700725A1 (ru) 2007-10-26
CA2580448A1 (en) 2006-04-13
DE602005025232D1 (de) 2011-01-20
PT1793844E (pt) 2011-03-10
GEP20104960B (en) 2010-04-26
DK1793844T3 (da) 2011-03-21
CN101056648A (zh) 2007-10-17
SG139750A1 (en) 2008-02-29
EA012650B1 (ru) 2009-12-30
EP1793844B1 (en) 2010-12-08
KR101191833B1 (ko) 2012-10-16
PL1793844T3 (pl) 2011-05-31
ZA200702610B (en) 2008-08-27
US20090081164A1 (en) 2009-03-26
AU2005290984B2 (en) 2010-09-09
CA2580448C (en) 2012-09-18
MX2007003387A (es) 2007-05-23
IL182362A0 (en) 2007-07-24
MA28950B1 (fr) 2007-10-01
AU2005290984A1 (en) 2006-04-13
US7772184B2 (en) 2010-08-10
EP1793844A1 (en) 2007-06-13
CN101056648B (zh) 2012-08-15
ATE490778T1 (de) 2010-12-15
UA88484C2 (ru) 2009-10-26
KR20070073761A (ko) 2007-07-10
RS51614B (en) 2011-08-31
HRP20110169T1 (hr) 2011-04-30
JP2008514690A (ja) 2008-05-08
BRPI0515494A (pt) 2008-07-29
CY1114594T1 (el) 2016-10-05
TNSN07084A1 (en) 2008-06-02

Similar Documents

Publication Publication Date Title
HK1104236A1 (en) Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin [d-meala]3-[etval]4
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
WO2005102392A3 (en) Combinations for treating hiv infection
WO2004052401A3 (en) Compositions and methods of delivery of pharmacological agents
WO2001091728A3 (en) Nanoemulsion formulations
ATE314092T1 (de) Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
TW200640487A (en) Combination of XOLAIR with immunosuppressive agent
WO2007007095A3 (en) Pharmaceutical compositions comprising a tgf-beta superfamily member
WO2006034001A3 (en) Methods of treating hiv infection
WO2005121138A3 (en) Heterotricyclic compounds for use as hcv inhibitors
WO2003082926A3 (en) Antimicrobial polymer conjugates
WO2005002522A3 (en) Compositions and methods for treating tissue ischemia
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
WO1998035694A3 (en) A pharmaceutical composition for treating hepatitis b virus (hbv) infection
EP1758923B8 (en) Peptide substance restoring myocardium function
UA93036C2 (ru) Лактамные соединения и применение в качестве фармацевтических препаратов
WO2002002763A3 (en) Recombinant staphylococcus aureus peptide deformylase
CU20070072A7 (es) Uso de [d-meala]3-[etval]4-ciclosporina para el tratamiento de infección por hepatitis c y composición farmacéutica que comprende la [d-meala]3-[etval]4-ciclosporina
WO2005056581A3 (en) Peptide able to specifically bind a chemokine receptor and use thereof
WO2003032728A3 (en) Methods for preventing or reversing asthma and compositions useful therefor
MXPA04006675A (es) Composicion farmaceutica que comprende glitazona y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.
Kyff Have You Seen the Tree?

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171003